← Back to Patent Explorer
US4851391A Expired / Lapsed US ⏱️ 0.0 years remaining

5-ethyl-2-deoxyuridine and urea composition for the treatment of viral diseases

Assignee: Robugen GmbH Pharmaceutische Fabrik
•
Filing: 1988-02-26
•
Granted: 1989-07-25
•
Expires: 2008-02-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel medicinal agent for the topical treatment of viral diseases, containing 5-ethyl-2'-deoxyuridine as the antivirally active compound and urea as the penetration-promoting compound, in an aqueous gel.

Inventors

  • 👤 Bernd Hempel
  • 👤 Ravindernath Kaul

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 12:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K47/00; A61K47/06; A61K47/16; A61K47/18; A61K9/00; A61K9/0012; A61K9/0014

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 33 words
A pharmaceutical composition for the topical treatment of viral diseases in man and animals, consisting of an antivirally effective amount of 5-ethyl-2'-deoxyuridine and a penetration-promoting amount of urea in a gel forming base.
Claim 2
Dependent Claim 33 words
A pharmaceutical composition for the topical treatment of viral diseases in man and animals, consisting of an antivirally effective amount of 5-ethyl-2'-deoxyuridine and a penetration-promoting amount of urea in a gel forming base.
Claim 3
Dependent Claim 35 words
The pharmaceutical composition according to claim 1 wherein said antiviral effective amount of 5-ethyl-2'-deoxyuridine comprises 1-5% by weight, and said penetration promoting amount of urea comprises 3-7% by weight, in an aqueous gel forming base.
Claim 4
Dependent Claim 24 words
A method of treating a viral disease in a mammal which comprises administering an antiviral effective amount of the composition according to claim 1.
Claim 5
Dependent Claim 14 words
The method according to claim 3 wherein said viral disease is caused by HSV-1.

References Cited (Backward Citations)

US4309989A Cited
US4239761A Cited
US4424232A Cited
US4652557A Cited
US4708965A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-07-24 1993-01-23 1993-07-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-07-24 1997-01-23 1997-07-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-07-24 2001-01-23 2001-07-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag